List of Qudexy Xr drug patents

Qudexy Xr is owned by Upsher Smith Labs.

Qudexy Xr contains Topiramate.

Qudexy Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Qudexy Xr was authorised for market use on 11 March, 2014.

Qudexy Xr is available in capsule, extended release;oral dosage forms.

Qudexy Xr can be used as treatment of seizures.

The generics of Qudexy Xr are possible to be released after 19 March, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US8889190 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US8652527 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QUDEXY XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in